Although earlier studies on EGFR-mutated LC were focused mainly on small-molecule drugs, the clinical activity of amivantamab, a dual EGFR and MET inhibitor, calls for reconsideration of this concept. This evidence concerns the gene EGFR and laryngotracheoesophageal cleft.